This site is for US healthcare professionals only. Visit the patient website.
Follow us: youtube facebook

en-US flag

English

  • language flag

    English

  • language flag

    German

  • language flag

    Italian

  • language flag

    Spanish

THERAKOS Photopheresis logo, representing advanced medical treatment.
Languages:

UVADEX® (methoxsalen) Sterile Solution is indicated for extracorporeal administration with the THERAKOS® CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of Cutaneous T-Cell Lymphoma (CTCL) that is unresponsive to other forms of treatment.

About us

Technical Clinical Support

Heading

Our company Therakos, is the leading company in Extracorporeal Photopheresis (ECP) delivery systems for autologous immunomodulatory therapy. With approvals for use in the U.S., Canada, Europe, Japan, Australia and Latin America our ECP platform was amongst the first immunomodulatory cell therapies of its kind expanding nearly 40 years of clinical use.

As a company, we are building toward a future where immune health is not simply managed. We are investing in science to research how immune health can be potentially restored. Our goal is to learn how to work with the immune system's own intelligence to help it become medicine's most powerful tool.

Customer Support

Leadership Team

The people driving Therakos forward combine deep immunology expertise, clinical rigor, and the ambition to reimagine immune therapy.

Slider Man Dog 1

Name Surname

Co-Chief Executive Officer

Lorem ipsum dolor sit amet consectetur. Scelerisque maecenas diam urna eget vel orci risus ipsum sit. Nibh mi porttitor quam magnis nibh eget ut dolor.

Slider Man Dog 1

Name Surname

Co-Chief Executive Officer

Lorem ipsum dolor sit amet consectetur. Scelerisque maecenas diam urna eget vel orci risus ipsum sit. Nibh mi porttitor quam magnis nibh eget ut dolor.

Slider Man Dog 1

Name Surname

Chief Medical Officer

Lorem ipsum dolor sit amet consectetur. Scelerisque maecenas diam urna eget vel orci risus ipsum sit. Nibh mi porttitor quam magnis nibh eget ut dolor.

Slider Man Dog 1

Name Surname

Co-Chief Executive Officer

Lorem ipsum dolor sit amet consectetur. Scelerisque maecenas diam urna eget vel orci risus ipsum sit. Nibh mi porttitor quam magnis nibh eget ut dolor.

Slider Man Dog 1

Name Surname

Co-Chief Executive Officer

Lorem ipsum dolor sit amet consectetur. Scelerisque maecenas diam urna eget vel orci risus ipsum sit. Nibh mi porttitor quam magnis nibh eget ut dolor.

Slider Man Dog 1

Name Surname

Chief Medical Officer

Lorem ipsum dolor sit amet consectetur. Scelerisque maecenas diam urna eget vel orci risus ipsum sit. Nibh mi porttitor quam magnis nibh eget ut dolor.

Scientific Advisory Board

Our Scientific Advisory Board brings together leading immunologists, oncologists, and cell therapy researchers who help shape the science behind our platform and challenge us to think further.

Slider Man Dog 1

Name Surname

Co-Chief Executive Officer

Institution: 
Lorem ipsum dolor sit amet

Area of Expertise: 
Lorem ipsum dolor sit amet

Slider Man Dog 1

Name Surname

Co-Chief Executive Officer

Institution: 
Lorem ipsum dolor sit amet

Area of Expertise: 
Lorem ipsum dolor sit amet

Slider Man Dog 1

Name Surname

Co-Chief Executive Officer

Institution: 
Lorem ipsum dolor sit amet

Area of Expertise: 
Lorem ipsum dolor sit amet

Slider Man Dog 1

Name Surname

Co-Chief Executive Officer

Institution: 
Lorem ipsum dolor sit amet

Area of Expertise: 
Lorem ipsum dolor sit amet

Slider Man Dog 1

Name Surname

Co-Chief Executive Officer

Institution: 
Lorem ipsum dolor sit amet

Area of Expertise: 
Lorem ipsum dolor sit amet

Slider Man Dog 1

Name Surname

Co-Chief Executive Officer

Institution: 
Lorem ipsum dolor sit amet

Area of Expertise: 
Lorem ipsum dolor sit amet

Slider Man Dog 1

Name Surname

Co-Chief Executive Officer

Institution: 
Lorem ipsum dolor sit amet

Area of Expertise: 
Lorem ipsum dolor sit amet

Slider Man Dog 1

Name Surname

Co-Chief Executive Officer

Institution: 
Lorem ipsum dolor sit amet

Area of Expertise: 
Lorem ipsum dolor sit amet

Our Shareholders

Strategic guidance from experienced leaders across biotechnology, medicine, and global health.

CVC_Capital_Partners_Logo.png

CVC Capital Partners

CVC is a leading private equity and investment advisory firm with a network of 24 offices throughout Europe, Asia and the US, with approximately US$115 billion of assets under management. Since its founding in 1981, CVC has secured commitments in excess of US$163 billion from some of the world's leading institutional investors across its private equity and credit strategies. Funds managed or advised by CVC are invested in over 90 companies worldwide, which have combined annual sales of approximately US$100 billion and employ more than 450,000 people.

The science is ready. The platform is growing. The next chapter in immune health is here.

INDICATIONS AND USAGE

UVADEX® (methoxsalen) Sterile Solution is indicated for extracorporeal administration with the THERAKOS® CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of Cutaneous T-Cell Lymphoma (CTCL) that is unresponsive to other forms of treatment.

IMPORTANT SAFETY INFORMATION

CAUTION: READ THE THERAKOS® CELLEX® PHOTOPHERESIS SYSTEM’S OPERATOR’S MANUAL PRIOR TO PRESCRIBING OR DISPENSING THIS MEDICATION.

UVADEX (methoxsalen) Sterile Solution should be used only by physicians who have special competence in the diagnosis and treatment of cutaneous T-cell lymphoma and who have special training and experience in the THERAKOS CELLEX Photopheresis System. Please consult the CELLEX Operator's Manual before using this product.

CONTRAINDICATIONS

UVADEX is contraindicated in:

  • Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, other psoralen compounds, or any of the excipients
  • Patients possessing a specific history of a light-sensitive disease state, including lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism
  • Patients with aphakia because of significantly increased risk of retinal damage
  • Patients that have contraindications to the photopheresis procedure

WARNINGS AND PRECAUTIONS

  • Patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal, and methyl orange may be at greater risk for photosensitivity reactions with UVADEX
  • Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic. Methoxsalen also causes DNA damage, interstrand cross-links and errors in DNA repair
  • Methoxsalen may cause fetal harm when given to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant.  If UVADEX is used during pregnancy, or if the patient becomes pregnant while receiving UVADEX, the patient should be apprised of the potential hazard to the fetus 
  • Severe photosensitivity can occur in patients treated with UVADEX. Advise patients to wear UVA absorbing, wrap-around sunglasses and cover exposed skin or use a sunblock (SPF 15 or higher), and avoid all exposure to sunlight for twenty-four (24) hours following photopheresis treatment
  • After methoxsalen administration, exposure to sunlight and/or ultraviolet radiation may result in "premature aging" of the skin
  • Since oral psoralens may increase the risk of skin cancers, monitor closely those patients who exhibit multiple basal cell carcinomas or who have a history of basal cell carcinomas
  • Serious burns from either UVA or sunlight (even through window glass) can result if the recommended dosage of methoxsalen is exceeded or precautions are not followed
  • Exposure to large doses of UVA light causes cataracts in animals. Oral methoxsalen exacerbates this toxicity
  • Safety in children has not been established
  • Thromboembolic events, such as pulmonary embolism and deep vein thrombosis, have been reported with UVADEX administration through photopheresis systems for treatment of patients with graft-versus-host disease, a disease for which UVADEX is not approved

ADVERSE REACTIONS

  • Side effects of photopheresis (UVADEX used with the THERAKOS Photopheresis Systems) were primarily related to hypotension secondary to changes in extracorporeal volume (>1%)

For the THERAKOS® CELLEX® Photopheresis Procedure:
INDICATIONS
The THERAKOS CELLEX Photopheresis System is indicated for use in the ultraviolet-A (UVA) irradiation, in the presence of the photoactive drug 8-methoxypsoralen (8-MOP), of extracorporeally circulating leukocyte-enriched blood, in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL), in persons who have not been responsive to other forms of treatment.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
The THERAKOS CELLEX Photopheresis System is not designated, sold, or intended for use except as indicated.

Certain underlying medical conditions contraindicate THERAKOS Photopheresis, including patients:

  • who cannot tolerate extracorporeal volume loss during the leukocyte-enrichment phase
  • exhibiting idiosyncratic or hypersensitivity reactions to 8-methoxypsoralen/psoralen compounds
  • with coagulation disorders
  • who have had previous splenectomy

WARNINGS AND PRECAUTIONS

  • THERAKOS Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure
  • Patients who may not be able to tolerate the fluid changes associated with extracorporeal photopheresis should be monitored carefully
  • Procedures, such as renal dialysis, which might cause significant fluid changes (and expose the patient to additional anticoagulation) should not be performed on the same day as extracorporeal photopheresis
  • Individual patients may require a heparin dosage that varies from the recommended dose to prevent post-treatment bleeding or clotting during a treatment

ADVERSE REACTIONS

  • Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension
  • Transient pyretic reactions, 37.7-38.9°C (100-102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction
  • Treatment frequency exceeding labeling recommendations may result in anemia
  • Venous access carries a small risk of infection and pain

Please see accompanying Full Prescribing Information, including the BOXED WARNING for UVADEX, and see the THERAKOS Photopheresis System Operator’s Manual.

 

IMPORTANT SAFETY INFORMATION
chevron-up chevron-down

CAUTION: READ THE THERAKOS® CELLEX® PHOTOPHERESIS SYSTEM’S OPERATOR’S MANUAL PRIOR TO PRESCRIBING OR DISPENSING THIS MEDICATION.

UVADEX (methoxsalen) Sterile Solution should be used only by physicians who have special competence in the diagnosis and treatment of cutaneous T-cell lymphoma and who have special training and experience in the THERAKOS CELLEX Photopheresis System. Please consult the CELLEX Operator's Manual before using this product.

Thank you for visiting therakos.com

You are leaving the therakos.com website.